Solutions the moment you need them
Our commitment is to provide high-quality solutions through the integration of technology, support, and expert knowledge — when it matters most. Explore our portfolio of therapies, designed to help manage critical imbalances and support patient care across diverse clinical fields.
Supporting balance. Protecting what matters.
*Not available in the US
Enabling independent CytoSorb® Therapy
*Not available for human use in the USA
Working with Ex Vivo Organ Perfusion to support the management of inflammatory processes
*Not available in the US
CytoSorb technology designed for veterinary critical-care applications
*Available only in the US
Additional Information
- Jansen et al., Crit Care 2023; 27(1):117
- Diab et al., Circ 2022; 145(13):959-968
- Scharf et al., Sci Rep 2021; 11(1);10190
- Albrecht et al., Blood Purif 2024; 53(2):88-95
- Hassan et al., JTCVS Open 2023; 15:190-196
- Chen J et al, Regenerative Biomaterials 2017; 4(1):31-37
- Waalders et al., Crit Care Med 2024; 52(4):e152-e153
- Bernardi et al., Crit Care 2016; 20(1):96
- Poli et al., Crit Care 2019; 23:108
- Gleason et al., Sem Thorac Cardiovasc Surg 2019; 31(4):783-793
- David et al., J Int Care 2017; 5:12
- Kogelmann et al., J Clin Med 2024; 13(1):294
- Soltesz et al., J Clin Med 2022; 11(12):6517
- Rugg C et al., Biomedicines 2020; 8(12):539
- Szigetvary et al., Biomed 2023; 11811):3068
- Riva et al., J Artif Orgs 2023; epub
- Grafe et al., Ren Fail 2023; 45(2):2259231
- Hassan et al., Ann Thor Cardiovasc Surg 2022; 28(3):186-192
- Hassan et al., Ann Thorac Surg 2019; 108(1):45-51
CytoSorb 300 IFU Indications (03/2023): CytoSorb is indicated for use in conditions where elevated levels of cytokines and/or bilirubin and/or myoglobin exist. CytoSorb is indicated for use intraoperatively during cardio-pulmonary bypass surgery for the removal of P2Y12-Inhibitor Ticagrelor and/or Factor Xa-Inhibitor Rivaroxaban. Results from current studies suggest that CytoSorb may be administered for up to 7 consecutive days. Maximum Treatment Time per Device: 24 Hours
PuriFi IFU Indications (07/2025):
PuriFi is indicated when a hemoperfusion procedure is prescribed by a physician and provides the required system environment of the prescribed adsorption column. The system environment includes equipment (PuriFi) used to drive, control, and monitor extracorporeal blood circulation, the tube set, and associated accessories such as vascular access devices and their interconnections. When used together with CytoSorbents’ wholeblood adsorption columns (Device), the system is intended to remove specific molecules as specified in the adsorption columns’ Instructions for Use.
ECOS-300CY IFU Indications (11/2022): ECOS is indicated for use during the ex vivo perfusion of harvested organs to remove inflammatory mediators from the perfusion solution by adsorption. ECOS has been shown to reduce levels of inflammatory mediators from Belzer and Steen perfusion solutions. Maximum Treatment Time per Device: 24 hours.
Voices around the world
